Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 04746L203 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Sermonix Pharmaceuticals, Inc.
13D
|
36.9% |
8/31/2026
Event 8/24/2026
|
||
| Sermonix Pharmaceuticals, Inc. | 36.9% | |||
| Portman David J. | 36.9% | |||
|
Perceptive Advisors LLC
13D/A
|
20.0% |
8/25/2026
Event 8/22/2026
|
||
| Perceptive Advisors LLC | 20.0% | |||
| Joseph Edelman | 20.0% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 16.5% | |||
| Perceptive Xontogeny Venture Fund II, LP | 3.8% | |||
|
Acorn Bioventures, L.P.
13G/A
|
12.1% |
8/20/2026
Event 8/18/2026
|
||
| Acorn Bioventures, L.P. | 5.1% | |||
| Acorn Capital Advisors GP, LLC | 5.1% | |||
| Acorn Bioventures 2, L.P. | 7.0% | |||
| Acorn Capital Advisors GP 2, LLC | 7.0% | |||
| Anders Hove | 12.1% | |||
|
ADAR1 Capital Management, LLC
13G
|
7.7% |
5/15/2026
Event 3/31/2026
|
||
| ADAR1 Capital Management, LLC | 7.7% | |||
| Daniel Schneeberger | 7.7% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
|
Baselake Partners, LP
13G/A
|
1.9% |
2/6/2026
Event 12/31/2025
|
||
| Baselake Partners, LP | 1.9% | |||
| Baselake Management, LLC | 1.9% | |||
| David Paolella | 1.9% | |||